Vascular effects of erythropoietin and anemia correction.
Since its introduction for clinical use a decade ago, recombinant human erythropoietin (rHuEPO) has revolutionized the management of the anemia of end-stage renal disease. Soon after its release, it became evident that the biological targets of rHuEPO were not limited to the erythroid progenitor cells. Instead, numerous clinical and laboratory studies have shown the modulatory action of rHuEPO on a wide array of cell types and organ systems. The present article is intended to provide an overview of the modulatory actions of rHuEPO on the production and action of vasoregulatory factors and its direct and indirect effects on vascular function and structure.
Division of Nephrology and Hypertension, University of California, Irvine 92868, USA. tabotten@uci.edu
N D
ND
Vaziri
D018798:Anemia, Iron-Deficiency / Q000188:drug therapy* / Q000209:etiology; D000818:Animals; D004730:Endothelium, Vascular / Q000187:drug effects; D004921:Erythropoietin / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D006973:Hypertension / Q000139:chemically induced*; D007676:Kidney Failure, Chronic / Q000150:complications; D008297:Male; D011994:Recombinant Proteins; D012084:Renin-Angiotensin System / Q000187:drug effects*; D018570:Risk Assessment; D012680:Sensitivity and Specificity; D014661:Vasoconstriction / Q000187:drug effects
D011994:Recombinant Proteins; D004921:Erythropoietin